These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 11817991

  • 1. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation.
    Hogan TJ, Elliott WJ, Seto AH, Bakris GL.
    Pharmacoeconomics; 2002; 20(1):37-47. PubMed ID: 11817991
    [Abstract] [Full Text] [Related]

  • 2. Economic evaluation of benazepril in chronic renal insufficiency.
    van Hout BA, Simeon GP, McDonnell J, Mann JF.
    Kidney Int Suppl; 1997 Dec; 63():S159-62. PubMed ID: 9407447
    [Abstract] [Full Text] [Related]

  • 3. Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
    Dickson M, Plauschinat CA.
    Am J Cardiovasc Drugs; 2008 Dec; 8(1):45-50. PubMed ID: 18303937
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of benazepril for advanced chronic renal insufficiency.
    Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW.
    N Engl J Med; 2006 Jan 12; 354(2):131-40. PubMed ID: 16407508
    [Abstract] [Full Text] [Related]

  • 5. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators.
    Lancet; 2010 Apr 03; 375(9721):1173-81. PubMed ID: 20170948
    [Abstract] [Full Text] [Related]

  • 6. Screening for proteinuria in US adults: a cost-effectiveness analysis.
    Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR.
    JAMA; 2003 Dec 17; 290(23):3101-14. PubMed ID: 14679273
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.
    Locatelli F, Carbarns IR, Maschio G, Mann JF, Ponticelli C, Ritz E, Alberti D, Motolese M, Janin G, Zucchelli P.
    Kidney Int Suppl; 1997 Dec 17; 63():S63-6. PubMed ID: 9407424
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.
    Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P.
    J Cardiovasc Pharmacol; 1999 Dec 17; 33 Suppl 1():S16-20; discussion S41-3. PubMed ID: 10028949
    [Abstract] [Full Text] [Related]

  • 10. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr 17; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

  • 11. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 17; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
    Vegter S, Tolley K, Keith MS, Lok CE, Soroka SD, Morton AR.
    Clin Ther; 2012 Jul 17; 34(7):1531-43. PubMed ID: 22742885
    [Abstract] [Full Text] [Related]

  • 13. An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Bilous RW.
    J Hum Hypertens; 2004 Oct 17; 18(10):733-8. PubMed ID: 15116142
    [Abstract] [Full Text] [Related]

  • 14. The cost effectiveness of ACE inhibitors as first-line antihypertensive therapy.
    Nordmann AJ, Krahn M, Logan AG, Naglie G, Detsky AS.
    Pharmacoeconomics; 2003 Oct 17; 21(8):573-85. PubMed ID: 12751915
    [Abstract] [Full Text] [Related]

  • 15. Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.
    Littlewood KJ, Greiner W, Baum D, Zoellner Y.
    BMC Nephrol; 2007 Jul 24; 8():9. PubMed ID: 17645811
    [Abstract] [Full Text] [Related]

  • 16. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
    Frei A, Palmer AJ, Burnier M, Hess B.
    Praxis (Bern 1994); 2006 Mar 15; 95(11):401-8. PubMed ID: 16570646
    [Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden.
    Ekman M, Bienfait-Beuzon C, Jackson J.
    J Hum Hypertens; 2008 Dec 15; 22(12):845-55. PubMed ID: 18633426
    [Abstract] [Full Text] [Related]

  • 18. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.
    Dtsch Med Wochenschr; 2004 Jan 02; 129(1-2):13-8. PubMed ID: 14703575
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA, Whitmire S, Patton S, Clark C, Blanchette CM, Howden R.
    J Med Econ; 2017 Jul 02; 20(7):715-722. PubMed ID: 28332417
    [Abstract] [Full Text] [Related]

  • 20. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand.
    Teerawattananon Y, Mugford M, Tangcharoensathien V.
    Value Health; 2007 Jul 02; 10(1):61-72. PubMed ID: 17261117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.